Medicover AB (publ)

LSE:0RPS Stock Report

Market Cap: SEK 26.2b

Medicover Valuation

Is 0RPS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0RPS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0RPS (SEK174.6) is trading below our estimate of fair value (SEK334.27)

Significantly Below Fair Value: 0RPS is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0RPS?

Key metric: As 0RPS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0RPS. This is calculated by dividing 0RPS's market cap by their current earnings.
What is 0RPS's PE Ratio?
PE Ratio114.8x
Earnings€19.70m
Market Cap€2.26b

Price to Earnings Ratio vs Peers

How does 0RPS's PE Ratio compare to its peers?

The above table shows the PE ratio for 0RPS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average20.1x
IDHC Integrated Diagnostics Holdings
13.6x23.7%US$225.8m
KOO Kooth
14.1x11.0%UK£60.4m
MDC Mediclinic International
21.9x10.7%UK£3.7b
SPI Spire Healthcare Group
30.9x27.3%UK£875.6m
0RPS Medicover
114.8x40.9%SEK 26.2b

Price-To-Earnings vs Peers: 0RPS is expensive based on its Price-To-Earnings Ratio (114.8x) compared to the peer average (19.6x).

Price to Earnings Ratio vs Industry

How does 0RPS's PE Ratio compare vs other companies in the European Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0RPS 114.8xIndustry Avg. 18.6xNo. of Companies8PE01020304050+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0RPS is expensive based on its Price-To-Earnings Ratio (114.8x) compared to the European Healthcare industry average (18.2x).

Price to Earnings Ratio vs Fair Ratio

What is 0RPS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0RPS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio114.8x
Fair PE Ratio53.4x

Price-To-Earnings vs Fair Ratio: 0RPS is expensive based on its Price-To-Earnings Ratio (114.8x) compared to the estimated Fair Price-To-Earnings Ratio (53.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0RPS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 174.60
SEK 214.68
+23.0%
10.4%SEK 240.33SEK 178.89n/a4
Nov ’25SEK 182.00
SEK 216.51
+19.0%
10.4%SEK 241.98SEK 180.11n/a4
Oct ’25SEK 186.00
SEK 212.20
+14.1%
9.7%SEK 237.74SEK 180.47n/a4
Sep ’25SEK 190.40
SEK 205.30
+7.8%
8.8%SEK 220.21SEK 179.80n/a3
Aug ’25SEK 188.80
SEK 207.63
+10.0%
9.3%SEK 222.20SEK 180.31n/a3
Jul ’25SEK 193.00
SEK 195.12
+1.1%
8.2%SEK 211.95SEK 173.48n/a3
Jun ’25SEK 195.80
SEK 199.13
+1.7%
8.2%SEK 220.14SEK 180.18n/a3
May ’25SEK 171.88
SEK 199.13
+15.9%
8.2%SEK 220.14SEK 180.18n/a3
Apr ’25SEK 138.00
SEK 190.26
+37.9%
5.4%SEK 203.56SEK 178.75n/a3
Mar ’25SEK 142.49
SEK 190.26
+33.5%
5.4%SEK 203.56SEK 178.75n/a3
Feb ’25SEK 170.30
SEK 201.25
+18.2%
9.0%SEK 220.52SEK 171.59n/a4
Jan ’25SEK 150.43
SEK 201.25
+33.8%
9.0%SEK 220.52SEK 171.59n/a4
Dec ’24SEK 141.97
SEK 213.90
+50.7%
10.6%SEK 236.19SEK 177.15n/a4
Nov ’24SEK 127.24
SEK 223.16
+75.4%
11.0%SEK 248.27SEK 183.14SEK 182.004
Oct ’24SEK 143.96
SEK 223.16
+55.0%
11.0%SEK 248.27SEK 183.14SEK 186.004
Sep ’24SEK 155.95
SEK 223.16
+43.1%
11.0%SEK 248.27SEK 183.14SEK 190.404
Aug ’24SEK 159.55
SEK 219.66
+37.7%
10.5%SEK 240.64SEK 180.48SEK 188.804
Jul ’24SEK 160.87
SEK 224.27
+39.4%
12.0%SEK 251.43SEK 179.69SEK 193.004
Jun ’24SEK 166.89
SEK 219.29
+31.4%
10.8%SEK 244.17SEK 180.49SEK 195.804
May ’24SEK 169.35
SEK 214.01
+26.4%
9.7%SEK 232.10SEK 179.95SEK 171.884
Apr ’24SEK 168.00
SEK 205.00
+22.0%
15.5%SEK 227.89SEK 150.37SEK 138.004
Mar ’24SEK 178.80
SEK 200.94
+12.4%
15.1%SEK 225.58SEK 148.85SEK 142.494
Feb ’24SEK 179.30
SEK 178.04
-0.7%
19.4%SEK 236.97SEK 150.04SEK 170.304
Jan ’24SEK 140.19
SEK 178.04
+27.0%
19.4%SEK 236.97SEK 150.04SEK 150.434
Dec ’23SEK 142.19
SEK 178.04
+25.2%
19.4%SEK 236.97SEK 150.04SEK 141.974
Nov ’23SEK 134.69
SEK 199.05
+47.8%
17.4%SEK 241.32SEK 153.09SEK 127.244

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Arjo

SEK 9.2b

Develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia and Pacific, South America, Africa, and internationally.

0HQ8

SEK 33.92

7D

-4.8%

1Y

-9.6%

Guerbet

€339.2m

Engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions.

0ELV

€27.00

7D

-9.8%

1Y

50.2%

Fagron

€1.3b

A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.

0HNZ

€18.06

7D

-6.1%

1Y

5.3%